bluuebunny/crossref_metadata_2025_split huggingface dataset:
Lived experience of people with lateral elbow tendinopathy: a qualitative study from the OPTimisE pilot and feasibility trial
Authors: Bateman Marcus , Hill Jonathan C , Cooper Karin , Littlewood Chris , Saunders Benjamin 
Published: August 2023

ObjectivesTo explore the lived experience of people with lateral elbow tendinopathy (LET) and its impact on everyday life.DesignQualitative semi-structured interviews, analysed using thematic analysis.SettingConducted as part of the mixed-methods OPTimisE pilot and feasibility randomised controlled trial of outpatient physiotherapy patients in the UK.Participants17 participants with LET, purposively sampled from the trial to provide representativeness based on age, sex, ethnicity, deprivation index and treatment allocation.ResultsFour themes were identified from the participants’ responses: (1) cause of onset—typically symptoms were attributed to: sudden changes in activity, repetitive work or compensating for other musculoskeletal conditions; (2) impact on everyday life—which included substantial impacts on quality-of-life, particularly due to pain disturbing sleep and difficulties performing daily tasks (related to work and hobbies) due to pain, although most reported being able to persevere with work; (3) self-help and understanding of the condition—with uncertainty about the appropriateness and potential harm of online advice and confusion from the diagnostic term ‘Tennis Elbow’ that non-sporting individuals struggled to relate to; (4) healthcare experiences—the treatments received were highly variable and often perceived as ineffectual.ConclusionsFor the first time, the lived experience of people from a range of backgrounds suffering from LET has been explored. Findings suggest that people frequently related the cause to a specific activity. They reported substantial impacts on daily tasks, sleep, work and hobbies. People also reported hesitancy to trust online information without formal healthcare advice, were confused by the common label of ‘Tennis Elbow’, and perceived the wide array of healthcare treatment options they had received to offer false hope and be largely ineffective. This study provides stimulus for clinicians to consider the advice and treatment provided, and whether the messages conveyed reflect the favourable natural history of the condition.Trial registration numberISRCTN64444585
TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment
Authors: van Elst Tessa , van Basten Jean-Paul A , van den Berg Pieter L , van den Bergh Roderick CN , Bloem Sjaak , van Dodewaard-de Jong Joyce M , Hendriks Mathijs P , Klaver Sjoerd O , Lalmahomed Zarina , Luijendijk Daphne , van de Luijtgaarden Addy CM , Roelofs Luc AJ , Vis André N , Vreugdenhil Gerard , Vrijhof Eric HJEJ , Wijsman Bart P , Bloemendal Haiko J , Mulders Peter FA , Mehra Niven 
Published: August 2023

IntroductionThe treatment landscape forde novometastatic hormone sensitive prostate cancer (mHSPC) is rapidly evolving. With an abundance of available treatment strategies, selecting the optimal strategy for an individual patient is becoming increasingly challenging. TripleAiM1 aims to evaluate the impact of mHSPC treatments on health-related quality of life (HRQoL) and to provide real-world data insights on diagnostics, treatment strategies, patient subgroups and related healthcare expenditure for mHSPC. The aspirational target of TripleAiM1 is that in the near future, a more tailored therapy can be offered based on the individual patient’s wishes and needs in accordance with the overarching principle of value-based healthcare.Methods and analysisWe describe the TripleAiM1 study design; a nationwide registry comprising a retrospective and prospective cohort of patients withde novomHSPC. Starting in May 2020, eligible patients are identified, selected and recruited in 14 participating hospitals in the Netherlands. Our hypothesis is that, in a real-world setting, differences in clinically meaningful HRQoL deterioration will be observed for treatment strategies over time. HRQoL data, assessed with patient-reported outcome measures, costs and clinical data will be collected for 24 months.For the retrospective cohort, all patients diagnosed withde novomHSPC from January 2017 onwards are eligible for inclusion. Patient and tumour characteristics, imaging modalities and treatment patterns will be analysed descriptively to provide a real-world overview.Time-to-event endpoints will be assessed using the Kaplan-Meier method and regression models will be employed to analyse baseline characteristics associated with an increased likelihood of death, progression and HRQoL deterioration. Longitudinal mixed-effects models will be employed to assess change of patient-reported outcome scores from baseline until the end of follow-up.Ethics and disseminationEthical approval was obtained from the Medical Research Ethics Committee, Twente. Study results will be published in peer-reviewed journals.Trial registration numberNL9719.
Diagnostic potential of plasma biomarkers and exhaled volatile organic compounds in predicting the different stages of acute mesenteric ischaemia: protocol for a multicentre prospective observational study (TACTIC study)
Authors: Duivenvoorden Annet A M , Clarysse Mathias , Ceulemans Laurens J , Geelkerken Robert H , Derikx Joep P M , de Vries Jean-Paul P M , Buscher Hessel C J L , Olde Damink Steven W M , van Schooten Frederik Jan , Lubbers Tim , Lenaerts Kaatje 
Published: August 2023

IntroductionAcute mesenteric ischaemia (AMI) is a life-threatening condition with short-term mortality of up to 80%. The diagnosis of AMI has remained troublesome due to the non-specific clinical presentation, symptoms and laboratory findings. Early unambiguous diagnosis of AMI is critical to prevent progression from reversible to irreversible transmural intestinal damage, thereby decreasing morbidity and improving survival. The present study aims to validate a panel of plasma biomarkers and investigate volatile organic compound (VOC) profiles in exhaled air as a tool to timely and accurately diagnose AMI.Methods and analysisIn this international multicentre prospective observational study, 120 patients (>18 years of age) will be recruited with clinical suspicion of AMI. Clinical suspicion is based on: (1) clinical manifestation, (2) physical examination, (3) laboratory measurements and (4) the physician’s consideration to perform a CT scan. The patient’s characteristics, repetitive blood samples and exhaled air will be prospectively collected. Plasma levels of mucosal damage markers intestinal fatty acid-binding protein and villin-1, as well as transmural damage marker smooth muscle protein 22-alpha, will be assessed by ELISA. Analysis of VOCs in exhaled air will be performed by gas chromatography time-of-flight mass spectrometry. Diagnosis of AMI will be based on CT, endovascular and surgical reports, clinical findings, and (if applicable) verified by histopathological examination.Ethics and disseminationThe study protocol was approved by the Medical Research Ethics Committee (METC) of Maastricht University Medical Centre+ and Maastricht University (METC azM/UM), the Netherlands (METC19-010) and the Ethics Committee Research UZ/KU Leuven, Belgium (S63500). Executive boards and local METCs of other Dutch participating centres Gelre Ziekenhuizen (Apeldoorn), Medisch Spectrum Twente (Enschede), and University Medical Centre Groningen have granted permission to carry out this study. Study results will be disseminated via open-access peer-reviewed scientific journals and national/international conferences.Trial registration numberNCT05194527.
Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome
Authors: Chen Jiayan , Qin Guanghao , Li Liangzhe , Qi Yifan , Che Huixin , Huang He , Xia Yang , Zhang Qing , Wu Yi , Yang Lanting , Moutari Salissou , Moore Jonathan E , Xu Ling , He Wei , Yu Sile , Pazo Emmanuel Eric , He Xingru 
Published: August 2023

IntroductionEvaporative dry eye (EDE) is common and can lead to ocular pain, decreased visual quality and reduced quality of life. Intense pulsed light (IPL) and 3% diquafosol ophthalmic solution have been found to be beneficial in reducing signs and symptoms of dry eye.Methods and analysisA randomised clinical trial will be performed at He Eye Specialist Hospital in Shenyang. 360 dry eye disease patients will be equally divided randomly into the IPL group, DQS group (3% diquafosol ophthalmic solution eye-drops) and IPL+group (IPL combined with 3% diquafosol eye-drops). All groups will be followed up for 4 weeks. The primary outcome measures will be the non-invasive tear break-up time and the Ocular Surface Disease Index change from the baseline. The secondary outcome measures willincludeconjunctival and cornea staining with fluorescein and lissamine, meibomian gland function and secretion quality, tear film lipid layer score, tear meniscus height, conjunctival hyperemia (redness score) changes . Adverse events also will be monitored and documented.DiscussionThis study aimed to assess whether the combination of IPL with 3% diquafosol ophthalmic solution (study group), IPL+ (study group), is more effective than IPL (active control group) or DQS (active control group) in participants with EDE.Ethics and disseminationManagement of dry eye with IPL combined with 3% diquafosol ophthalmic solution, registered on 23 January 2023. Ethics approval number: IRB (2022) K029.01. The study’s findings will be shared regardless of the effect’s direction.Trial registration numberNCT05694026.
Prediction of violence or threat of violence among employees in social work, healthcare and education: the Finnish Public Sector cohort study
Authors: Airaksinen Jaakko , Pentti Jaana , Seppälä Piia , Virtanen Marianna , Ropponen Annina , Elovainio Marko , Kivimäki Mika , Ervasti Jenni 
Published: August 2023

ObjectivesTo develop a risk prediction algorithm for identifying work units with increased risk of violence in the workplace.DesignProspective cohort study.SettingPublic sector employees in Finland.Participants18 540 nurses, social and youth workers, and teachers from 4276 work units who completed a survey on work characteristics, including prevalence and frequency of workplace violence/threat of violence at baseline in 2018–2019 and at follow-up in 2020–2021. Those who reported daily or weekly exposure to violence or threat of violence daily at baseline were excluded.ExposuresMean scores of responses to 87 survey items at baseline were calculated for each work unit, and those scores were then assigned to each employee within that work unit. The scores measured sociodemographic characteristics and work characteristics of the work unit.Primary outcome measureIncrease in workplace violence between baseline and follow-up (0=no increase, 1=increase).ResultsA total of 7% (323/4487) of the registered nurses, 15% (457/3109) of the practical nurses, 5% of the social and youth workers (162/3442) and 5% of the teachers (360/7502) reported more frequent violence/threat of violence at follow-up than at baseline. The area under the curve values estimating the prediction accuracy of the prediction models were 0.72 for social and youth workers, 0.67 for nurses, and 0.63 for teachers. The risk prediction model for registered nurses included five work unit characteristics associated with more frequent violence at follow-up. The model for practical nurses included six characteristics, the model for social and youth workers seven characteristics and the model for teachers included four characteristics statistically significantly associated with higher likelihood of increased violence.ConclusionsThe generated risk prediction models identified employees working in work units with high likelihood of future workplace violence with reasonable accuracy. These survey-based algorithms can be used to target interventions to prevent workplace violence.
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Authors: Shah Bijal D , Cassaday Ryan D , Park Jae H , Houot Roch , Oluwole Olalekan O , Logan Aaron C , Boissel Nicolas , Leguay Thibaut , Bishop Michael R , Topp Max S , Tzachanis Dimitrios , O'Dwyer Kristen M , Arellano Martha L , Lin Yi , Baer Maria R , Schiller Gary J , Subklewe Marion , Abedi Mehrdad , Minnema Monique C , Wierda William G , DeAngelo Daniel J , Stiff Patrick J , Jeyakumar Deepa , Mao Daqin , Adhikary Sabina , Zhou Lang , Schuberth Petra C , Damico Khalid Rita , Ghobadia Armin 
Published: August 2023

BackgroundBrexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the USA for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and in the European Union for patients ≥26 years with R/R B-ALL. After 2 years of follow-up in ZUMA-3, the overall complete remission (CR) rate (CR+CR with incomplete hematological recovery (CRi)) was 73%, and the median overall survival (OS) was 25.4 months in 78 Phase 1 and 2 patients with R/R B-ALL who received the pivotal dose of brexu-cel. Outcomes by prior therapies and subsequent allogeneic stem cell transplantation (alloSCT) are reported.MethodsEligible adults had R/R B-ALL and received one infusion of brexu-cel (1×10⁶ CAR T cells/kg) following conditioning chemotherapy. The primary endpoint was the CR/CRi rate per central review. Post hoc subgroup analyses were exploratory with descriptive statistics provided.ResultsPhase 1 and 2 patients (N=78) were included with median follow-up of 29.7 months (range, 20.7–58.3). High CR/CRi rates were observed across all prior therapy subgroups examined: 1 prior line of therapy (87%, n=15) and ≥2 prior lines (70%, n=63); prior blinatumomab (63%, n=38) and no prior blinatumomab (83%, n=40); prior inotuzumab (59%, n=17) and no prior inotuzumab (77%, n=61); and prior alloSCT (76%, n=29) and no prior alloSCT (71%, n=49). The frequency of Grade ≥3 cytokine release syndrome, neurological events, and treatment-related Grade 5 adverse events were largely similar among prior therapy subgroups.Median duration of remission (DOR) in responders with (n=14) and without (n=43) subsequent alloSCT was 44.2 (95% CI, 8.1 to not estimable (NE)) and 18.6 months (95% CI, 9.4 to NE); median OS was 47.0 months (95% CI, 10.2 to NE) and not reached (95% CI, 23.2 to NE), respectively. Median DOR and OS were not reached in responders without prior or subsequent alloSCT (n=22).ConclusionsIn ZUMA-3, adults with R/R B-ALL benefited from brexu-cel, regardless of prior therapies and subsequent alloSCT status, though survival appeared better in patients without certain prior therapies and in earlier lines of therapy. Additional studies are needed to determine the impact prior therapies and subsequent alloSCT have on outcomes of patients who receive brexu-cel.
Persistent high prevalence of modifiable cardiovascular risk factors among patients with osteoarthritis in the UK in 1992–2017
Authors: Yu Dahai , Huang Xiaoyang , Mamas Mamas A , Wilkie Ross 
Published: August 2023

ObjectivesTo compare the annual and period prevalence of modifiable cardiovascular risk factors (MCVRFs) between populations with and without osteoarthritis (OA) in the UK over 25 years.Methods215 190 patients aged 35 years and over from the UK Clinical Practice Research Datalink GOLD database who were newly diagnosed OA between 1992 and 2017, as well as 1:1 age-matched, sex-matched, practice-matched and index year-matched non-OA individuals, were incorporated. MCVRFs including smoking, hypertension, type 2 diabetes, obesity and dyslipidaemia were defined by Read codes and clinical measurements. The annual and period prevalence and prevalence rate ratios (PRRs) of individual and clustering (≥1, ≥2 and ≥3) MCVRFs were estimated by Poisson regression with multiple imputations for missing values.ResultsThe annual prevalence of MCVRFs increased in the population with OA between 1992 and 2017 and was consistently higher in the population with OA compared with the population without OA between 2004 and 2017. Trends towards increased or stable annual PRRs for individuals and clustering of MCVRFs were observed. A 26-year period prevalence of single and clustering MCVRFs was significantly higher in individuals with OA compared with non-OA individuals. Period PRRs were higher in Southern England, women and increased with age for most MCVRFs except for obesity, which has the higher PRR in the youngest age group.ConclusionsA consistently higher long-term prevalence of MCVRFs was observed in individuals with OA compared to those without OA. The higher prevalence of obesity in the youngest age group with OA highlights the need for public health strategies. Further research to understand MCVRF management in OA populations is necessary.
Staff well-being in UK children’s hospices: a national survey
Authors: Bedendo Andre , Papworth Andrew , Taylor Johanna , Beresford Bryony , Mukherjee Suzanne , Fraser Lorna , Ziegler Lucy 
Published: August 2023

ObjectivesPoor psychological well-being among healthcare workers can have numerous negative impacts, but evidence about levels of burnout in children’s hospice care staff is limited. This study aimed to determine the prevalence of burnout and to explore the association between staff characteristics and support mechanisms with burnout among children’s hospice care staff in the UK.MethodsTwo national online surveys collecting data on hospice care staff psychological well-being and hospice organisational characteristics. All children’s hospices in the UK were invited.Thirty-one hospices (out of 52) responded to the hospice survey and 583 staff responded to the staff survey. Data collection took place between May and December 2020 and measures included the Copenhagen Burnout Inventory, Work Engagement and the Health and Safety Executive Management Standards Indicator Tool.ResultsBurnout prevalence was 11% and mean burnout score was 32.5 (SD: 13.1). Burnout levels were independent of working arrangements (eg, working from home or at the hospice) during the COVID-19 pandemic. Hospices performed well in most management standards, but poorly on the ‘Control’ domain. The average Work Engagement score for staff was 7.5 (SD: 1.5).ConclusionsBurnout levels for staff in children’s hospices in the UK were lower than in other healthcare settings, with this comparing to 17.3% among palliative care staff generally. Overall, hospices performed well in management standards and there was no indication of urgent action needed. Work Engagement in our sample was higher compared with other National Health Service workers during the COVID-19 pandemic.
Chiral perturbation theory of the hyperfine splitting in (muonic) hydrogen
Authors: Hagelstein Franziska , Lensky Vadim , Pascalutsa Vladimir 
Published: August 2023

AbstractThe ongoing experimental efforts to measure the hyperfine transition in muonic hydrogen prompt an accurate evaluation of the proton-structure effects. At the leading order in$$\alpha $$α, which is$$O(\alpha ^5)$$O(α5)in the hyperfine splitting (hfs), these effects are usually evaluated in a data-driven fashion, using the empirical information on the proton electromagnetic form factors and spin structure functions. Here we perform a first calculation based on the baryon chiral perturbation theory (B$$\chi $$χPT). At leading orders it provides a prediction for the proton polarizability effects in hydrogen (H) and muonic hydrogen ($$\mu $$μH). We find large cancellations among the various contributions leading to, within the uncertainties, a zero polarizability effect at leading order in the B$$\chi $$χPT expansion. This result is in significant disagreement with the current data-driven evaluations. The small polarizability effect implies a smaller Zemach radius$$R_\textrm{Z}$$RZ, if one uses the well-known experimental 1Shfs in H or the 2Shfs in$$\mu $$μH. We, respectively, obtain$$R_\textrm{Z}(\textrm{H}) = 1.010(9)$$RZ(H)=1.010(9)fm,$$R_\textrm{Z}(\mu \textrm{H}) = 1.040(33)$$RZ(μH)=1.040(33)fm. The total proton-structure effect to the hfs at$$O(\alpha ^5)$$O(α5)is then consistent with previous evaluations; the discrepancy in the polarizability is compensated by the smaller Zemach radius. Our recommended value for the 1Shfs in$$\mu \text {H}$$μHis$$182.640(18)\,\textrm{meV}.$$182.640(18)meV.
$$B\pi $$ excited-state contamination in lattice calculations of B-meson correlation functions
Authors: Bär Oliver , Broll Alexander , Sommer Rainer 
Published: August 2023

AbstractMulti-particle states with additional pions are expected to result in a difficult-to-control excited-state contamination in lattice simulations. We show that heavy meson chiral perturbation theory can be employed to estimate the contamination due to two-particle$$B\pi $$Bπstates in variousB-meson observables, like theB-meson decay constant and the$$B^*B\pi $$B∗Bπcoupling. We work in the static limit and to next-to-leading order in the chiral expansion, i.e. including$$\textrm{O}(p).$$O(p).The$$B\pi $$Bπstates are found to typically lead to an overestimation of the observables at the few percent level. We determine two of the LECs from$$B\rightarrow \pi $$B→πform factor computations of the KEK group (Colquhoun et al. in Phys. Rev. D 106:054502, 2022) and discuss ways to determine the others. In particular, one LEC which is associated with smeared interpolating fields seems to be easily accessible and thus opens up a way to systematically study the effect of smearing on excited-state effects.
Gene–Environment Analyses in a UK Biobank Skin Cancer Cohort Identifies Important SNPs in DNA Repair Genes That May Help Prognosticate Disease Risk
Authors: Jeremian Richie , Xie Pingxing , Fotovati Misha , Lefrançois Philippe , Litvinov Ivan V. 
Published: August 2023

AbstractBackground:Despite well-established relationships between sun exposure and skin cancer pathogenesis/progression, specific gene–environment interactions in at-risk individuals remain poorly-understood.Methods:We leveraged a UK Biobank cohort of basal cell carcinoma (BCC, n = 17,221), cutaneous squamous cell carcinoma (cSCC, n = 2,331), melanoma in situ (M-is, n = 1,158), invasive melanoma (M-inv, n = 3,798), and healthy controls (n = 448,164) to quantify the synergistic involvement of genetic and environmental factors influencing disease risk. We surveyed 8,798 SNPs from 190 DNA repair genes, and 11 demographic/behavioral risk factors.Results:Clinical analysis identified darker skin (RR = 0.01–0.65) and hair (RR = 0.27–0.63) colors as protective factors. Eleven SNPs were significantly associated with BCC, three of which were also associated with M-inv. Gene–environment analysis yielded 201 SNP–environment interactions across 90 genes (FDR-adjusted q &lt; 0.05). SNPs from the FANCA gene showed interactions with at least one clinical factor in all cancer groups, of which three (rs9926296, rs3743860, rs2376883) showed interaction with nearly every factor in BCC and M-inv.Conclusions:We identified novel risk factors for keratinocyte carcinomas and melanoma, highlighted the prognostic value of several FANCA alleles among individuals with a history of sunlamp use and childhood sunburns, and demonstrated the importance of combining genetic and clinical data in disease risk stratification.Impact:This study revealed genome-wide associations with important implications for understanding skin cancer risk in the context of the rapidly-evolving field of precision medicine. Major individual factors (including sex, hair and skin color, and sun protection use) were significant mediators for all skin cancers, interacting with &gt;200 SNPs across four skin cancer types.